CPX-351: all 62 studies that test it
Page 1 of 1. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.
- Vyxeos® With Clofarabine for Pediatric AMLRecruitingNCT07156435Phase 1
- Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)RecruitingNCT07008638Phase 1/2
- A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid LeukemiaNot yet recruitingNCT06182592Phase 3
- Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial TreatmentNot yet recruitingNCT05628623Phase 2
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingNCT05564390Phase 2
- CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AMLRecruitingNCT05558124Phase 1
- Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)Not yet recruitingNCT05554419Phase 2
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)RecruitingNCT05554406Phase 2
- Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AMLRecruitingNCT05024552Phase 1
- Phase IB/II of CPX-351 for Relapse Prevention in AMLRecruitingNCT04990102Phase 1/2
- CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT04493164Phase 2
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsRecruitingNCT04293562Phase 3
- Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After InductionRecruitingNCT04049539Phase 1/2
- CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaRecruitingNCT03896269Phase 1
- Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute LeukemiaRecruitingNCT03826992Phase 1
- Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid LeukemiaRecruitingNCT03629171Phase 2
- Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid NeoplasmsActive, not recruitingNCT05656248Phase 2Results posted
- Vyxeos for Induction of Low- or Intermediate-risk.Active, not recruitingNCT05599360Phase 2Results posted
- CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual DiseaseTerminatedNCT04526288Phase 2Results posted
- CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years OldCompletedNCT04269213Phase 2Results posted
- CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid LeukemiaActive, not recruitingNCT04231851Phase 2Results posted
- A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid LeukemiaTerminatedNCT04209725Phase 2Results posted
- CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit PatientsCompletedNCT04195945Phase 2Results posted
- Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid LeukemiaTerminatedNCT03988205Phase 4Results posted
- CPX-351 Therapy for MDS After Hypomethylating Agent FailureTerminatedNCT03957876Phase 2Results posted
- Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative NeoplasmsTerminatedNCT03878199Phase 1/2Results posted
- Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid LeukemiaCompletedNCT03844997Phase 1/2Results posted
- Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic LeukemiaCompletedNCT03575325Phase 2Results posted
- Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid LeukemiaCompletedNCT03335267Phase 2Results posted
- Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid LeukemiaCompletedNCT03226418Phase 2Results posted
- Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02642965Phase 1/2Results posted
- CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid LeukemiaCompletedNCT02286726Phase 2Results posted
- An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS PatientsCompletedNCT02238925Phase 2Results posted
- CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT02019069Phase 2Results posted
- Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01804101Not applicableResults posted
- Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid LeukemiaCompletedNCT01696084Phase 3Results posted
- Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)CompletedNCT00822094Phase 2Results posted
- Trial of CPX-351 in Newly Diagnosed Elderly AML PatientsCompletedNCT00788892Phase 2Results posted
- A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to TreatWithdrawnNCT05320380Phase 1/2
- Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative NeoplasmCompletedNCT04992949Phase 2
- Induction Therapy for Patients With FLT3 Mutated Acute Myeloid LeukemiaWithdrawnNCT04982354Phase 1/2
- Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid LeukemiaCompletedNCT04915612Phase 1
- CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDSActive, not recruitingNCT04668885Phase 2
- CPX-351 in Higher Risk Myelodysplastic SyndromesCompletedNCT04273802Phase 1/2
- Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid LeukemiaCompletedNCT04230239Phase 2
- A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCTActive, not recruitingNCT04217278Phase 2/3
- Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic SyndromeActive, not recruitingNCT04128748Phase 1/2
- CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.WithdrawnNCT04109690Phase 1/2
- Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AMLCompletedNCT04061239Phase 2
- A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AMLCompletedNCT04038437Phase 1
- CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid LeukemiaTerminatedNCT03904251Phase 1
- Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse GeneticsActive, not recruitingNCT03897127Phase 3
- CPX-351 Plus Enasidenib for Relapsed AMLActive, not recruitingNCT03825796Phase 2
- Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic SyndromeCompletedNCT03672539Phase 2
- CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic SyndromeActive, not recruitingNCT03572764Phase 1
- A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351CompletedNCT03555955Phase 1
- CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic SyndromeCompletedNCT03393611Phase 1
- Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy CombinationsStatus unknownNCT02272478Phase 2/3
- Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic ImpairmentWithdrawnNCT02269579Phase 2
- Safety Study of CPX-351 in Children With Relapsed Leukemia or LymphomaCompletedNCT01943682Phase 1
- A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)CompletedNCT00875693Phase 1
- Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.CompletedNCT00389428Phase 1